Scantox Group announced the launch of the Scantox DuplexSeq Mutagenesis App, hosted on an upgraded bioinformatics platform for its DuplexSeq Mutagenesis Assay kits and services. The launch restores customer access to DuplexSeq Mutagenesis Assays on stronger foundations: reagent kits available now with expanded supply in Q3 2026, and an upgraded bioinformatics pipeline built for scale.
"The DuplexSeq platform is now faster, more accessible, and positioned for the expanding role of error-corrected sequencing in genomic safety," said Matt Tate, PhD, Chief Business Development Officer at Scantox. "Bringing in Clint Valentine, the original pipeline architect, to lead this migration was a deliberate decision to give customers full confidence in the upgraded platform. DuplexSeq is the leading error-corrected sequencing methodology for nonclinical mutagenesis assessment, and it is now ready to deliver on that promise at scale."
"We built the original DuplexSeq pipeline to be scientifically rigorous and computationally durable, and migrating to LatchBio was a straightforward process," said Clint Valentine, Vice President of Operations at Fulcrum Genomics. "Testing against TwinStrand's original validation dataset confirmed equivalent outputs and full pipeline continuity. The platform is better, and the science is unchanged."
Scantox selected LatchBio, following an evaluation of available bioinformatics platforms, for its user experience and fit for regulated nonclinical science. The Scantox DuplexSeq Mutagenesis App enables one-click execution of the validated mutation analysis pipeline, centralised data and project management, improved data visualisation, and sponsor-tailored reporting. Existing customers can upload historical study data directly to the new platform and will be contacted with onboarding details.
"DuplexSeq customers operate in a regulated environment where data integrity, traceability, and audit readiness are non-negotiable," said Kyle Giffin, Chief Operating Officer of LatchBio. "LatchBio was built to meet those standards, with 21 CFR Part 11 controls, immutable audit trails, and SOC 2 Type II certified infrastructure."
